Exhibit 99.1
| |
|
|
|
|
|
|
IMMEDIATE RELEASE
CONTACTS:
Brent Larson,
Vice President / CFO
614 822.2330
|
|
February 10, 2009
Lee
Stern,
The Trout Group
646.378.2922 |
NEOPROBE HIRES V.P. OF PHARMACEUTICAL RESEARCH & CLINICAL DEVELOPMENT
Frederick O. Cope, Ph.D. to Join Neoprobe Executive Team
DUBLIN, OHIO — February 10, 2009 — Neoprobe Corporation (OTCBB: NEOP), a diversified developer of
innovative oncology and cardiovascular surgical and diagnostic products, announced today that
Frederick O. Cope, Ph.D. will be joining Neoprobe Corporation as its Vice President of
Pharmaceutical Research and Clinical Development.
Dr. Cope has most recently served as the Assistant Director for Research and Head of Program
Research Development for The Ohio State University Comprehensive Cancer Center, The James Cancer
Hospital and The Richard J. Solove Research Institute. Dr. Cope also served for a number of years
as the Ernest W. Volwiler Fellow and Head, Cancer and AIDS Research Effort for Abbot
Laboratories-Ross Division. Dr. Cope is active in a number of professional and scientific
organizations such as serving as a current Ad Hoc Candidate of the FDA Scientific Advisory Panel, a
member of Emory University’s Informatics Advisory Board, and as a full member of the American
Society of Clinical Oncology. Dr. Cope received his BSc from the Delaware Valley College of Science
and Agriculture, his MS from Millersville University of Pennsylvania and his Ph.D. from the
University of Connecticut.
David Bupp, Neoprobe’s President and CEO, said, “Neoprobe is very pleased to have someone with Dr.
Cope’s pharmaceutical development, clinical and regulatory experience join our management team.
Fred is joining us at an exciting point in our corporate development as we work through the pivotal
clinical trials and prepare for the regulatory submissions to support marketing clearance for
Lymphoseek® and as we make visible progress in reinvigorating our development activities related to
RIGScan® CR. We look forward to his contributions to our team and to the success of Neoprobe
Corporation.”
Fred Cope, Neoprobe’s Vice President of Pharmaceutical Research and Clinical Development, said, “I
look forward to becoming part of the Neoprobe team and to the approval of the initial applications
of Lymphoseek. This successful program will provide a unique and remarkably valuable tool for the
benefit of patients, and I believe, set a new standard in intra-operative diagnosis. I look forward
to contributing to the Lymphoseek program and supporting Neoprobe’s other development initiatives.”
Lymphoseek is a proprietary radioactive tracing agent being developed for use in connection with
gamma detection devices in a surgical procedure known as Intraoperative Lymphatic Mapping (ILM). A
Phase 3 multi-center clinical trial for Lymphoseek in patients with breast cancer or melanoma is
underway and a protocol for a second Phase 3 clinical study to evaluate the efficacy of Lymphoseek
as a sentinel lymph node tracing agent in patients with head and neck squamous cell carcinoma has
been submitted to the U.S. Food and Drug Administration and the European Medicines Agency.
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by
meeting the critical intraoperative diagnostic information needs of physicians and therapeutic
treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma
detection systems that are widely used by cancer surgeons and is commercializing the
Quantix® line of blood flow measurement products developed by its subsidiary,
Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related
biomedical systems and radiopharmaceutical agents including Lymphoseek® and
RIGScan® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy
technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder
return by maximizing its strong position in gamma detection technologies and diversifying into new,
synergistic biomedical markets through continued investment and selective acquisitions.
www.neoprobe.com